Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 ...
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...
GlobalData on MSN
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial
The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.
AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, ...
With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...
AstraZeneca (AZN) climbed 3.1% as Bernstein reaffirms outperform rating, citing non-oncology portfolio as undervalued driver ...
View AstraZeneca PLC AZN stock quote prices, financial information, real-time forecasts, and company news from CNN.
Follow the latest headlines from ABC News, Australia's most trusted media source, with live events, audio and on-demand video ...
Bloomberg on MSN
AstraZeneca broadens US growth push
AstraZeneca CFO Aradhana Sarin discusses how the pharmaceutical company is broadening its US shareholder base and plans to ...
By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill baxdrostat had been approved in the United States, offering a new treatment option ...
The U.K. drugmaker recently direct-listed its shares in the U.S., betting on a new-drug pipeline to achieve its revenue target by 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results